PNPLA3 and diabetes mellitus: Another study found that among 220 individuals who were started on semaglutide (for approved indications of diabetes and obesity, not for MASLD), those ﻿carrying at least 1 ﻿PNPLA3 risk allele experienced larger decreases in ALT afterward and were more likely to develop a clinically relevant decrease in ALT of ﻿≥17 U/L, which has been previously shown to correlate with histologic response.127